Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2469]

Breakthrough announced in treatment of patient with rare type of leukaemia

Breakthrough announced in treatment of patient with rare type of leukaemia

ASCO GI: New, rationally-based chemotherapy combination appears highly effective in patients with treatment-resistant neuroendocrine tumours

ASCO GI: New, rationally-based chemotherapy combination appears highly effective in patients with treatment...

Breast cancer patients experience fewer side effects from anticancer drug when receiving either real or sham acupuncture

Breast cancer patients experience fewer side effects from anticancer drug when receiving either real or sham...

Advanced radiation therapy for head and neck cancer may be better than traditional radiation at preventing side effects and cancer recurrence

Advanced radiation therapy for head and neck cancer may be better than traditional radiation at preventing side...

FDA approval for combination of trametinib with dabrafenib for treatment of melanoma

FDA approval for combination of trametinib with dabrafenib for treatment of melanoma

SABCS 2013: Presurgery treatment combination more effective for women with triple-negative breast cancer

SABCS 2013: Presurgery treatment combination more effective for women with triple-negative breast cancer

SABCS 2013: Bisphosphonate treatment fails to improve outcomes for women with chemoresistant breast cancer

SABCS 2013: Bisphosphonate treatment fails to improve outcomes for women with chemoresistant breast cancer

SABCS 2013: Study identifies highly effective treatment option for patients with HER2- positive breast cancer

SABCS 2013: Study identifies highly effective treatment option for patients with HER2- positive breast cancer

ASH 2013: Final stage II results of the CLL11 trial

ASH 2013: Final stage II results of the CLL11 trial

ASH 2013: Bcl-2 inhibitor ABT-199 monotherapy shows anti-tumour activity in high-risk chronic lymphocytic leukaemia and small lymphocytic lymphoma

ASH 2013: Bcl-2 inhibitor ABT-199 monotherapy shows anti-tumour activity in high-risk chronic lymphocytic...

More from ecancer